Latest NeuroSense Therapeutics News & Updates

See the latest news and media coverage for NeuroSense. We track all announcements, press releases, and industry mentions in real time, all in one place.

NeuroSense Therapeutics (NeuroSense)

Late-stage clinical biotechnology company developing neurodegenerative disease therapies

neurosense-tx.com

Headquarters: Cambridge, United States
Founded year: 2017
Company type: Public company
Number of employees: 26–50
Industry: Pharmaceuticals

Last updated October 13

Latest news about NeuroSense Therapeutics (NeuroSense)

In short: NeuroSense targeted 2027 revenue, appealed Nasdaq delisting and advanced PrimeC in ALS and brain injury.

Company announcements

October 13 NeuroSense

NeuroSense secures Nasdaq hearing date

The company regains bid-price compliance and plans to present a strategy for market value standards while advancing PrimeC toward regulatory filings in December 2026.

October 2 NeuroSense

NeuroSense regains Nasdaq bid price compliance but faces listing appeal

The biotech company appeals a delisting notice regarding market value while confirming stock trades above $1.00 per share after a reverse split.

September 25 NeuroSense

NeuroSense provides H1 2026 business update and financial results

The company reports reduced operating expenses and targets a December NDS filing in Canada for PrimeC.

June 29 NeuroSense

NeuroSense achieves primary endpoint in Phase 2b ALS study

TDP-43 reduction with statistical significance, supporting PrimeC's disease-modifying potential.

Media coverage

August 22 Finanznachrichten

NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update

2025 marked transition of PrimeC into a late-stage clinical asset with FDA-cleared Phase 3 program in ALS Statistically significant survival benefit demonstrated, including 65% reduction...

August 6 Yahoo Finance

NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced that it is targeting...

June 25 The Globe and Mail

NeuroSense's ALS Drug PrimeC Shows Strong Phase 2b Results in JAMA Neurology

Detailed price information for Neurosense Therapeutics Ltd (NRSN-Q) from The Globe and Mail including charting and trades.

June 9 ALS News Today

Neurosense, Health Canada discuss approval path for PrimeC

The FDA, after providing positive feedback on the trial's design, cleared Neurosense to initiate PARAGON late last year. The study expects to enroll about 300...

Never miss news about NeuroSense

Track NeuroSense and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

NeuroSense competitors & trending companies

Browse news for competitors to NeuroSense and other trending companies.